Optimi Health Corp. (Nasdaq: OPTH; CSE: OPTI; FSE: 8BN) has completed a production batch of pharmaceutical-grade MDMA intended to supply clinical and commercial programs in Canada, Israel and Australia.
The finished capsules were manufactured at Optimi’s Good Manufacturing Practice facility in Princeton, British Columbia, under the company’s Health Canada Drug Establishment Licence. Optimi said the batch contains enough product for a proposed Canadian Phase 3 trial, an approved Israeli clinical study and its next planned commercial shipment to Australia.
The Canadian study is expected to enroll up to 100 veterans and current or former frontline workers with post-traumatic stress disorder. Participants would receive two supervised sessions combining Optimi’s synthetic MDMA hydrochloride with psychotherapy, spaced several weeks apart.
The study’s primary efficacy endpoint will measure changes in PTSD severity using the Clinician-Administered PTSD Scale, known as CAPS-5. Optimi describes the trial as Health Canada-authorized but continues to refer to it as proposed. Enrollment has not started, and the company expects the study to begin in 2027.
“The medicine for that trial is already made,” CEO and co-founder Dane Stevens said.
The same batch is expected to supply an Israeli Ministry of Health-approved PTSD study operated through the Healing October 7th project in partnership with MAPS Israel. Optimi did not announce a shipment date or disclose the financial terms associated with that program.
The company also plans to export MDMA capsules to Australia before the end of 2026. Australia permits specifically authorized psychiatrists to prescribe MDMA for PTSD under the Therapeutic Goods Administration’s Authorised Prescriber Scheme. These products remain unapproved therapeutic goods and can only be supplied through controlled access pathways.
Completing production reduces one manufacturing requirement but does not provide evidence that MDMA-assisted therapy is safe or effective. Optimi did not disclose the batch size, production cost or potential revenue from the three programs.
Financial capacity improved following Optimi’s 2026 Nasdaq offering. The company reported C$13.07 million in cash as of June 30 after raising C$20.7 million in gross proceeds before offering costs.
For the nine months ended June 30, Optimi recorded C$239,700 in revenue, down from C$490,330 during the comparable period, and a net loss of approximately C$5.55 million. The offering strengthened the balance sheet but increased the company’s outstanding share count and diluted existing shareholders.
Upcoming Catalysts
- Export of the next commercial MDMA shipment to Australia
- Shipment or deployment of capsules for the Israeli clinical study
- Additional details about the Canadian Phase 3 protocol and trial sites
- Initiation and enrollment of the Canadian trial, expected in 2027
- Updated revenue, cash and operating-loss figures
Sources
- Optimi Health Completes MDMA Production for Three PTSD Programs — October 20, 2026
- Optimi Announces Canadian Phase 3 PTSD Trial Plans — September 16, 2026
- Optimi Management’s Discussion and Analysis for the Period Ended June 30, 2026 — SEC
- Optimi Interim Financial Statements for the Period Ended June 30, 2026 — SEC
- MDMA and Psilocybine Access in Australia — Therapeutic Goods Administration
Editorial Disclosure
This article is based entirely on publicly available information, including company announcements, regulatory guidance and securities filings. Securities discussed or referenced include Optimi Health Corp. (Nasdaq: OPTH; CSE: OPTI; FSE: 8BN). Biotech Stocks Daily has not received compensation from Optimi Health, its management, investor relations representatives or any third party for this specific article. Biotech Stocks Daily may have current or past paid business relationships with other companies, which do not influence the content or conclusions of this article. No staff member or principal of Biotech Stocks Daily holds a position in any security mentioned at the time of publication.
Sources used include Optimi’s October 20, 2026 production announcement, its September 16, 2026 clinical-trial announcement, financial statements and management discussion filed with the SEC, and guidance from Australia’s Therapeutic Goods Administration. Information concerning the production batch, proposed clinical programs and planned shipments originated primarily from Optimi and has not been independently validated by Biotech Stocks Daily.
Optimi’s MDMA products have not received market authorization from Health Canada. The proposed Canadian Phase 3 trial has not started, and enrollment, trial execution and results remain uncertain. Completing production does not demonstrate safety, efficacy or regulatory approval. MDMA products accessed in Australia remain unapproved therapeutic goods supplied through controlled regulatory pathways.
Financial information is reported in Canadian dollars and reflects Optimi’s position as of June 30, 2026. The company generated limited revenue and recorded an operating loss during the reported period. Its 2026 public offering strengthened its cash position but resulted in shareholder dilution. Additional development, manufacturing or commercialization activities may require further financing.
Biotechnology and pharmaceutical securities are speculative investments carrying significant risk, including the potential total loss of capital. Coverage on Biotech Stocks Daily is provided for informational and educational purposes only. Biotech Stocks Daily is not a registered investment advisor. Nothing in this article constitutes financial, investment or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making investment decisions. For more information, please see our full DISCLAIMER.
